Skip to main content
Top
Published in: Clinical and Translational Oncology 11/2020

01-11-2020 | Cervical Cancer | Research Article

Invasive and in situ cervical cancer associated with pregnancy: analysis from the French cancer network (CALG: Cancer Associé à La Grossesse)

Authors: A. Puchar, A. S. Boudy, L. Selleret, A. Arfi, C. Owen, S. Bendifallah, E. Darai

Published in: Clinical and Translational Oncology | Issue 11/2020

Login to get access

Abstract

Purpose

To describe the oncologic and obstetric outcomes of patients diagnosed with invasive cervical cancer (ICC) and in situ adenocarcinoma (ISA) during pregnancy or during the year following delivery.

Methods

This retrospective observational study involved a cohort of 28 patients diagnosed with invasive cervical cancer (20 patients) or in situ adenocarcinoma (eight patients) during pregnancy or during the year following delivery who received expert opinion from physicians of the Cancer Associé à La Grossesse (CALG) network between 2005 and 2018. Descriptive results were expressed in median, range and interquartile range (IQR).

Results

Between 2005 and 2018, 20 patients with ICC and eight with ISA received expert opinion from physicians of the CALG network. Both ICC and ISA were mostly diagnosed during pregnancy with a median term at diagnosis of 23.3 weeks of gestation (WG) for ICC and 7.3 WG for ISA. Overall, the median age at diagnosis for both ICC and ISA was 33 years. Most ICCs (n = 9) had FIGO stage ≥ IB2 and five underwent neoadjuvant chemotherapy at a median term of 22.5 WG. Seventeen patients with ICC underwent surgery. Three patients had medical termination of the pregnancy. Two patients experienced recurrence and three died. Median time of follow-up was 59.3 months (IQR 30.5–129.2).

Conclusion

Management of cervical cancer during pregnancy is challenging especially in terms of maternal outcomes with a relative poor prognosis requiring a multidisciplinary expert advice.
Literature
1.
2.
go back to reference McCormick A, Peterson E. Cancer in pregnancy. Obstet Gynecol Clin N Am. 2018;45:187–200.CrossRef McCormick A, Peterson E. Cancer in pregnancy. Obstet Gynecol Clin N Am. 2018;45:187–200.CrossRef
3.
go back to reference Mitchell K, Saraiya M, Bhatt A. Increasing HPV vaccination rates through national provider partnerships. J. Womens Health. 2019;28:747–51.CrossRef Mitchell K, Saraiya M, Bhatt A. Increasing HPV vaccination rates through national provider partnerships. J. Womens Health. 2019;28:747–51.CrossRef
4.
go back to reference Smith LH, Danielsen B, Allen ME, et al. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. Am J Obstet Gynecol. 2003;189:1128–35.CrossRef Smith LH, Danielsen B, Allen ME, et al. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. Am J Obstet Gynecol. 2003;189:1128–35.CrossRef
5.
go back to reference Eibye S, Kjær SK, Mellemkjær L. Incidence of pregnancy-associated cancer in Denmark, 1977–2006. Obstet Gynecol. 2013;122:608–17.CrossRef Eibye S, Kjær SK, Mellemkjær L. Incidence of pregnancy-associated cancer in Denmark, 1977–2006. Obstet Gynecol. 2013;122:608–17.CrossRef
6.
go back to reference Mathews TJ, Hamilton BE. First births to older women continue to rise. NCHS data brief, no 152. Hyattsville, MD: National Center for Health Statistics; 2014. Mathews TJ, Hamilton BE. First births to older women continue to rise. NCHS data brief, no 152. Hyattsville, MD: National Center for Health Statistics; 2014.
7.
go back to reference Thomeer MG, Gerestein C, Spronk S, et al. Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis. Eur Radiol. 2013;23:2005–188.CrossRef Thomeer MG, Gerestein C, Spronk S, et al. Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis. Eur Radiol. 2013;23:2005–188.CrossRef
8.
go back to reference Mitchell DG, Snyder B, Coakley F, et al. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol. 2006;24:5687–94.CrossRef Mitchell DG, Snyder B, Coakley F, et al. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol. 2006;24:5687–94.CrossRef
9.
go back to reference Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143:22–36.CrossRef Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143:22–36.CrossRef
11.
go back to reference Song Y, Liu Y, Lin M, et al. Efficacy of neoadjuvant platinum-based chemotherapy during the second and third trimester of pregnancy in women with cervical cancer: an updated systematic review and meta-analysis. Drug Des Dev Ther. 2019;13:79–102.CrossRef Song Y, Liu Y, Lin M, et al. Efficacy of neoadjuvant platinum-based chemotherapy during the second and third trimester of pregnancy in women with cervical cancer: an updated systematic review and meta-analysis. Drug Des Dev Ther. 2019;13:79–102.CrossRef
12.
go back to reference Kärrberg C, Rådberg T, Holmberg E, et al. Support for down-staging of pregnancy-associated cervical cancer. Acta Obstet Gynecol Scand. 2015;94:654–9.CrossRef Kärrberg C, Rådberg T, Holmberg E, et al. Support for down-staging of pregnancy-associated cervical cancer. Acta Obstet Gynecol Scand. 2015;94:654–9.CrossRef
13.
go back to reference Pettersson BF, Hellman K, Vaziri R, et al. Cervical cancer in the screening era: who fell victim in spite of successful screening programs? J Gynecol Oncol. 2011;22:76–82.CrossRef Pettersson BF, Hellman K, Vaziri R, et al. Cervical cancer in the screening era: who fell victim in spite of successful screening programs? J Gynecol Oncol. 2011;22:76–82.CrossRef
14.
go back to reference Zappa M, Visioli CB, Ciatto S, et al. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer. 2004;90:1784–6.CrossRef Zappa M, Visioli CB, Ciatto S, et al. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer. 2004;90:1784–6.CrossRef
15.
go back to reference Castanon A, Landy R, Sasieni PD. Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix? Int J Cancer. 2016;139:1040–5.CrossRef Castanon A, Landy R, Sasieni PD. Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix? Int J Cancer. 2016;139:1040–5.CrossRef
16.
go back to reference Mancini S, Ravaioli A, Giuliani O, et al. Incidence and survival trends of cervical adenocarcinoma in Italy: cytology screening has become more effective in downstaging the disease but not in detecting its precursors. Int J Cancer. 2017;140:247–8.CrossRef Mancini S, Ravaioli A, Giuliani O, et al. Incidence and survival trends of cervical adenocarcinoma in Italy: cytology screening has become more effective in downstaging the disease but not in detecting its precursors. Int J Cancer. 2017;140:247–8.CrossRef
17.
go back to reference Davy MLJ, Dodd TJ, Luke CG, et al. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol. 2003;101:38–45.PubMed Davy MLJ, Dodd TJ, Luke CG, et al. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol. 2003;101:38–45.PubMed
18.
go back to reference Pirog EC. Cervical adenocarcinoma: diagnosis of human papillomavirus-positive and human papillomavirus-negative tumors. Arch Pathol Lab Med. 2017;141:1653–67.CrossRef Pirog EC. Cervical adenocarcinoma: diagnosis of human papillomavirus-positive and human papillomavirus-negative tumors. Arch Pathol Lab Med. 2017;141:1653–67.CrossRef
19.
go back to reference Morimura Y, Fujimori K, Soeda S. Cervical cytology during pregnancy—comparison with non-pregnant women and management of pregnant women with abnormal cytology. Fukushima J Med Sci. 2002;48(1):27–37 (PubMed PMID 12365596).CrossRef Morimura Y, Fujimori K, Soeda S. Cervical cytology during pregnancy—comparison with non-pregnant women and management of pregnant women with abnormal cytology. Fukushima J Med Sci. 2002;48(1):27–37 (PubMed PMID 12365596).CrossRef
20.
go back to reference La Russa M, Jeyarajah AR. Invasive cervical cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33:44–57.CrossRef La Russa M, Jeyarajah AR. Invasive cervical cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33:44–57.CrossRef
21.
go back to reference Thomeer MG, Gerestein C, Spronk S, van Doorn HC, van der Ham E, Hunink MG. Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis. Eur Radiol. 2013;23:2005–188.CrossRef Thomeer MG, Gerestein C, Spronk S, van Doorn HC, van der Ham E, Hunink MG. Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis. Eur Radiol. 2013;23:2005–188.CrossRef
22.
go back to reference Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola M, Schwartz LH, Woodward P, Hricak HPH. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol. 2006;24:5687–94.CrossRef Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola M, Schwartz LH, Woodward P, Hricak HPH. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol. 2006;24:5687–94.CrossRef
23.
go back to reference Michael CW, Esfahani FM. Pregnancy-related changes: a retrospective review of 278 cervical smears. Diagn Cytopathol. 1997;17:99–107.CrossRef Michael CW, Esfahani FM. Pregnancy-related changes: a retrospective review of 278 cervical smears. Diagn Cytopathol. 1997;17:99–107.CrossRef
24.
go back to reference Salvo G, Frumovitz M, Pareja R, et al. Simple trachelectomy with pelvic lymphadenectomy as a viable treatment option in pregnant patients with stage IB1 ( ≥ 2 cm) cervical cancer: bridging the gap to fetal viability. Gynecol Oncol. 2018;150:50–5.CrossRef Salvo G, Frumovitz M, Pareja R, et al. Simple trachelectomy with pelvic lymphadenectomy as a viable treatment option in pregnant patients with stage IB1 ( ≥ 2 cm) cervical cancer: bridging the gap to fetal viability. Gynecol Oncol. 2018;150:50–5.CrossRef
25.
go back to reference Umemoto M, Ishioka S, Mizugaki Y, et al. Obstetrical prognosis of patients who underwent vaginal radical trachelectomy during pregnancy. J Obstet Gynaecol Res. 2019;45:1167–72.CrossRef Umemoto M, Ishioka S, Mizugaki Y, et al. Obstetrical prognosis of patients who underwent vaginal radical trachelectomy during pregnancy. J Obstet Gynaecol Res. 2019;45:1167–72.CrossRef
26.
go back to reference Yoshihara K, Ishiguro T, Chihara M, et al. The safety and effectiveness of abdominal radical trachelectomy for early-stage cervical cancer during pregnancy. Int J Gynecol Cancer. 2018;28:782–7.CrossRef Yoshihara K, Ishiguro T, Chihara M, et al. The safety and effectiveness of abdominal radical trachelectomy for early-stage cervical cancer during pregnancy. Int J Gynecol Cancer. 2018;28:782–7.CrossRef
27.
go back to reference Perrone AM, Bovicelli A, D’Andrilli G, et al. Cervical cancer in pregnancy: analysis of the literature and innovative approaches. J Cell Physiol. 2019;234:14975–90.CrossRef Perrone AM, Bovicelli A, D’Andrilli G, et al. Cervical cancer in pregnancy: analysis of the literature and innovative approaches. J Cell Physiol. 2019;234:14975–90.CrossRef
28.
go back to reference Cibula D, Pötter R, Planchamp F, et al. The European society of gynaecological oncology/European society for radiotherapy and oncology/European society of pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer. 2018;28:641–55.CrossRef Cibula D, Pötter R, Planchamp F, et al. The European society of gynaecological oncology/European society for radiotherapy and oncology/European society of pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer. 2018;28:641–55.CrossRef
29.
go back to reference Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5:283–91.CrossRef Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5:283–91.CrossRef
30.
go back to reference Köhler C, Oppelt P, Favero G, et al. How much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy. Am J Obstet Gynecol. 2015;213(206):e1–5. Köhler C, Oppelt P, Favero G, et al. How much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy. Am J Obstet Gynecol. 2015;213(206):e1–5.
31.
go back to reference Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34:302–12.CrossRef Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34:302–12.CrossRef
Metadata
Title
Invasive and in situ cervical cancer associated with pregnancy: analysis from the French cancer network (CALG: Cancer Associé à La Grossesse)
Authors
A. Puchar
A. S. Boudy
L. Selleret
A. Arfi
C. Owen
S. Bendifallah
E. Darai
Publication date
01-11-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 11/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02343-5

Other articles of this Issue 11/2020

Clinical and Translational Oncology 11/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine